View Post

Startup joins Roche to hold clinical trials for double-whammy cancer drug

In Clinical Trials by Barbara Jacoby

By: Shoshanna Solomon From: DSP-107, developed by KAHR Medical, hopes to have dual impact: tag cancer cells, and boost activity of the immune cells that target them KAHR Medical, an Israeli biopharmaceutical company, says it is developing a second generation class of  immunotherapy drugs that it hopes will be more effective in tackling cancer, based on the lessons learned …